Endophthalmitis after intravitreal injections

Bibliography

• Schwartz SG, Flynn HW Jr, Scott IU. Endophthalmitis: classification and current management. Exp Rev Ophthalmol 2007;2(3):385-96
   Google Scholar
• Ho J, Loewenstein JI. Endophthalmitis associated with intravitreal injections. Int Ophthalmol Clin 2007;47(2):199-208
   PubMedGoogle Scholar
• Stepien KE, Eaton AM, Jafee GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in Spring 2006. Retina 2009;29(2):207-13
   PubMed Web of Science ®Google Scholar
• Jonisch J, Lai JC, Deramo VA, et al. Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. Br J Ophthalmol 2008;92(8):1051-4
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Bakri SJ, et al. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005;36(1):24-9
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Scott IU, Flynn HW Jr, Puliafito CA. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004;138(3):489-92
   PubMed Web of Science ®Google Scholar
• Sharma MC, Lai WW, Shapiro MJ. Pseudohypopyon following intravitreal triamcinolone acetonide injection. Cornea 2004;23(4):398-9
   PubMed Web of Science ®Google Scholar
• Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121(9):1279-82
   PubMed Web of Science ®Google Scholar
• Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87(8):972-4
   PubMed Web of Science ®Google Scholar
• Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin®). Br J Ophthalmol 2008. [Epub ahead of print]
   Google Scholar
• Yenerel NM, Dinc UA, Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008;24(3):326-63
   Google Scholar
• Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246(5):779-81
   PubMed Web of Science ®Google Scholar
• Available from: http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---February/23/Reports-of-eye-inflammation-and-sterile-endophthalmitis-following-intravitreal-bevacizumab-Avastin/ [Accessed 4 June 2009]
   Google Scholar
• Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007;91(9):1122-4
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141(3):579-80
   PubMed Web of Science ®Google Scholar
• Chen SD, Lochhead J, Patel CK. Diffuse intraocular dispersion of triamcinolone particles as a cause of sterile endophthalmitis. Arch Ophthalmol 2004;122(11):1733
   PubMedGoogle Scholar
• Marticorena J, Gomez-Ulla F, Romano MR, Luna I. Repeated pseudoendophthalmitis after combined photodynamic therapy and intravitreal triamcinolone. Graefes Arch Clin Exp Ophthalmol 2007;245(9):1403-4
   PubMedGoogle Scholar
• Amato JE, Lee DH, Santos BA, Akduman L. Steroid hypopyon following intravitreal triamcinolone acetonide injection in a pseudophakic patient. Ocul Immunol Inflam 2005;13(2-3):245-7
   PubMed Web of Science ®Google Scholar
• Yoon SJ, Rhee DY, Marx JL, et al. Anatomic and visual outcomes of noninfectious endophthalmitis after intravitreal triamcinolone. Am J Ophthalmol 2009;147(6):1031-6
   PubMed Web of Science ®Google Scholar
• Roth DB, Flynn HW. Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am J Ophthalmol 2008;146(3):346-7
   PubMed Web of Science ®Google Scholar
• Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23(5):686-91
   PubMed Web of Science ®Google Scholar
• Roth DB, Chieh J, Spirn MJ, et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121(9):1279-82
   PubMed Web of Science ®Google Scholar
• Mahajan VB, Folk JC, Boldt HC. A head-tilt test for hypopyon after intravitreal triamcinolone. Retina 2009;29(4):560-1
   PubMedGoogle Scholar
• Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805-16
   PubMed Web of Science ®Google Scholar
• Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a Phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;133:633-42
   Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432-44
   PubMed Web of Science ®Google Scholar
• Rosenfeld PR, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31
   PubMed Web of Science ®Google Scholar
• Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthlamol 2008;145(5):862-74
   PubMed Web of Science ®Google Scholar
• Bhavsar AR, Ip MS, Glassman AR, et al. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007;144(3):454-6
   PubMed Web of Science ®Google Scholar
• Artunay O, Yuzbasioglu E, Rasier R, et al. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009. [Epub ahead of print]
   Google Scholar
• Diago T, McCannel CA, Bakri SJ, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009. In press
   PubMedGoogle Scholar
• Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28(10):1395-9
   PubMed Web of Science ®Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9
   PubMed Web of Science ®Google Scholar
• Jonas JB, Spandau UH, Schlictenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 2008;22(4);590-1
   PubMed Web of Science ®Google Scholar
• Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology 2009;116(6):1225
   PubMedGoogle Scholar
• Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye 2007;21(3):317-20
   PubMed Web of Science ®Google Scholar
• Mason JO 3rd, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28(4):564-7
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6
   PubMed Web of Science ®Google Scholar
• Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145(5):879-82
   PubMed Web of Science ®Google Scholar
• Westfall AC, Osborn A, Kuhl D, et al. Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 2005;123:1075-7
   PubMed Web of Science ®Google Scholar
• Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin (R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthlamol 2008;246(1):81-7
   PubMed Web of Science ®Google Scholar
• Miller JJ, Scott IU, Flynn HW, et al. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005;139(6):983-7
   PubMed Web of Science ®Google Scholar
• Scott IU, Flynn HW Jr, Dev S, et al. Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina 2008;28(1):138-42
   PubMed Web of Science ®Google Scholar
• Eifrig CW, Flynn HW Jr, Scott IU, Newton J. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers 2002;33(5):373-8
   PubMedGoogle Scholar
• Scott IU, Flynn HW. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27(1):10-2
   PubMed Web of Science ®Google Scholar
• Lad EM, Moshfeghi DM. Minimizing the risk of endophthalmitis following intravitreal injections. Compr Ophthalmol Update 2006;7(6):277-84
   PubMedGoogle Scholar
• Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24(Suppl 5):S3-19
   PubMed Web of Science ®Google Scholar
• Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991;98:1769-75
   PubMed Web of Science ®Google Scholar
• Safar A, Dellimore MC. The effect of povidone iodine flush versus drops on conjunctival colonization before intravitreal injections. Int Ophthalmol 2007;27(5):307-12
   PubMedGoogle Scholar
• de Caro JJ, Ta CN, Ho HK, et al. Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. Retina 2008;28(6):877-83
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Starr MB, Basket S. Bacterial endophthalmitis prophylaxis for cataract surgery. An evidence-based update. Ophthlamology 2002;109:13-26
   PubMed Web of Science ®Google Scholar
• Scott IU, Flynn HW. The role of topical antibiotic prophylaxis for intravitreal injections. Arch Ophthlamol 2007;125(7):974-6
   PubMedGoogle Scholar
• Deramo VA, Lai JC, Fastenberg DM, Udell IJ. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol 2006;142:721-5
   PubMed Web of Science ®Google Scholar
• Meyer CH, Mennel S, Eter N. Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application. Ophthalmologe 2007;104(11):952-7
   PubMed Web of Science ®Google Scholar
• Miller D, Flynn PM, Scott IU, et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 2006;124:479-83
   PubMed Web of Science ®Google Scholar
• Bhavsar AR. A consecutive series of 1,000 intravitreous injections without topical antibiotic prophylaxis. Invest Ophthalmol Vis Sci 2008;49:e-Abstract 5617
   PubMedGoogle Scholar
• Javey G, Kapoor N, Rosenfeld PJ. Elimination of post-injection topical antibiotics after intravitreal injections. Invest Ophthalmol Vis Sci 2009;50: e-Abstract 5016
   Google Scholar
• Taban M, Singh RP, Chung JY, et al. Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am J Ophthalmol 2007;144(1):50-4
   PubMed Web of Science ®Google Scholar
• Alexandrou TJ, Hariprasad SM, Benevento J, et al. Reduction of preoperative conjunctival bacterial flora with the use of mupirocin nasal ointment. Trans Am Ophthalmol Soc 2006;104:196-201
   PubMedGoogle Scholar
• Aggio FB, Farah ME, de Melo GB, et al. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye 2007;21(3):408-9
   PubMed Web of Science ®Google Scholar
• Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-96
   PubMedGoogle Scholar
• Han DP, Wisniewsi SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1-17
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol 2004;121:345-50
   Google Scholar
• Park-Wyllie LY, Juurlink DM, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61
   PubMed Web of Science ®Google Scholar
• Smiddy WE, Smiddy RJ, Ba'Arath B, et al. Subconjunctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. Retina 2005;25:751-8
   PubMedGoogle Scholar
• Tetsuju S, Iida T, Kaneko H, Saito M. Cytomegalovirus retinitis after intravitreal triamcinolone acetonide in an immunocompetent patient. Jpn J Ophthalmol 2008;52(5):414-6
   PubMed Web of Science ®Google Scholar
• Park YS, Byeon SH. Cytomegalovirus retinitis after intravitreous triamcionlone injection in a patient with central retinal vein occlusion. Korean J Ophthalmol 2008;22(2);143-4
   PubMedGoogle Scholar
• Delyfer MN, Rougier MB, Hubschman JP, et al. Cytomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases. Acta Ophthalmol Scand 2007;85(6):681-3
   PubMedGoogle Scholar
• Saidel MA, Berreen J, Margolis TP. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol 2005;140(6):1141-3
   PubMed Web of Science ®Google Scholar
• Aggermann T, Stolba U, Brunner S, Binder S. Endophthalmitis with retinal necrosis following intravitreal triamcionlone acetonide injection. Ophthalmologica 2006;220(2):131-3
   PubMedGoogle Scholar
• Benz MS, Murray TG, Dubovy SR, et al. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone. Arch Ophthalmol 2003;121:271-3
   PubMed Web of Science ®Google Scholar
• Alkuraya HS, Al-Kharashi AS, Alharthi E, Chaudry IA. Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. Int Ophthalmol 2008. [Epub ahead of print]
   Google Scholar
• Murray RJ, Aravena-Roman M, Kampfer P. Endophthalmitis due to Williamsia muralis. J Med Microbiol 2007;56:1410-2
   PubMedGoogle Scholar